[Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].
The effectiveness of orchiectomy plus an antigonadotropic therapy alone (ethinylestradiol sulfonate), of orchiectomy plus a combined hormone and chemotherapy (ethinylestradiol sulfonate plus vincristine/vinblastine, cyclophosphamide, methotrexate) and of orchiectomy plus chemotherapy (vincristine/vinblastine, cyclophosphamide, methotrexate) alone for the initial treatment of advanced (stage IV) carcinoma of the prostate was compared. The cumulative 4-year survival rate was better after combined hormone and chemotherapy. Our results do not justify the administration of combined hormone and chemotherapy in previously untreated advanced carcinoma of the prostate.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011897:Random Allocation
D004997:Ethinyl Estradiol
Kombinierte Hormon-Chemotherapie versus alleinige Hormontherapie in der Initialbehandlung des fortgeschrittenen Prostatakarzinoms--eine prospektive Kooperativstudie